Zydus Launches Generic Adempas In US Market

LIFESCIENCES: Zydus Lifesciences Ltd. has launched the first generic version of Adempas, or riociguat tablets, in the United States in partnership with MSN Laboratories. The launch marks another addition to the company’s generic pharmaceutical portfolio in the US market and expands its presence in the segment through a partnership-led commercial opportunity. Riociguat is the active pharmaceutical ingredient associated with Adempas, and the launch provides a generic alternative in the US market following the applicable regulatory and commercial processes. The partnership with MSN Laboratories brings together the respective capabilities of the companies for the launch and supply of the product. The US generics market remains an important market for Indian pharmaceutical companies, with product launches providing opportunities to expand portfolios across various therapeutic categories. Actual commercial performance from the product will depend on market demand, pricing, competition, prescription trends, distribution, market share and other factors. The launch is therefore an operational and product-development update for Zydus Lifesciences and should be viewed in the context of the company’s broader US business. Market participants may track subsequent company disclosures for further information regarding product performance, additional launches and developments in the company’s US generics portfolio. This information is shared strictly as a corporate and market update for informational purposes and should not be considered investment advice, research analysis, or a recommendation to buy or sell any security.